(HEPA) –
-
Hepion Pharmaceuticals (HEPA) Winds Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
-
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
-
Form 10-K Hepion Pharmaceuticals, For: Dec 31
-
Form NT 10-K Hepion Pharmaceuticals, For: Dec 31
-
Form 4 Hepion Pharmaceuticals, For: Mar 06 Filed by: Purcell Michael J.
-
Form 3 Hepion Pharmaceuticals, For: Mar 05 Filed by: Purcell Michael J.
-
Hepion Pharmaceuticals (HEPA) Appoints Michael Purcell to its Board
-
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
-
Form 4 Hepion Pharmaceuticals, For: Feb 19 Filed by: Block Timothy M.
-
Form 4 Hepion Pharmaceuticals, For: Feb 19 Filed by: BRANCACCIO JOHN P
-
Form 4 Hepion Pharmaceuticals, For: Feb 19 Filed by: JACOB GARY S
-
Form 4 Hepion Pharmaceuticals, For: Feb 19 Filed by: Lbiati Kaouthar
-
Form 8-K Hepion Pharmaceuticals, For: Feb 20
-
Form 8-K Hepion Pharmaceuticals, For: Feb 15
-
Hepion Pharmaceuticals (HEPA) Exercises $2M of Warrants
-
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
-
Form SC 13G Hepion Pharmaceuticals, Filed by: ARMISTICE CAPITAL, LLC
-
Form 8-K Hepion Pharmaceuticals, For: Feb 07
-
Hepion Pharmaceuticals to Present at NASH-TAG 2024
-
Form 8-K Hepion Pharmaceuticals, For: Dec 27
-
Brookline Capital Markets Downgrades Hepion Pharma (HEPA) to Hold
-
Form 8-K Hepion Pharmaceuticals, For: Dec 04
-
Hepion Pharmaceuticals (HEPA) Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
-
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
-
Hepion Pharmaceuticals (HEPA) Halted, News Pending
-
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
-
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
-
Form 4 Hepion Pharmaceuticals, For: Nov 24 Filed by: Wijngaard Peter
-
Form 10-Q Hepion Pharmaceuticals, For: Sep 30
-
Form NT 10-Q Hepion Pharmaceuticals, For: Sep 30
-
Hepion Pharmaceuticals (HEPA) Reports Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
-
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
-
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
-
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
-
Form EFFECT Hepion Pharmaceuticals,
-
Hepion Pharmaceuticals (HEPA) Announces 1.96M Share Offering by Selling Stockholders
-
Form S-1 Hepion Pharmaceuticals,
-
Hepion Pharmaceuticals' (HEPA) Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
-
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
-
Form D Hepion Pharmaceuticals,
-
Form 8-K Hepion Pharmaceuticals, For: Sep 28
-
Form 424B5 Hepion Pharmaceuticals,
-
Hepion Pharmaceuticals (HEPA) Prices 980K Share Offering at $5.10/sh
-
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
-
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
-
New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program
-
Form 4 Hepion Pharmaceuticals, For: Sep 15 Filed by: Wijngaard Peter
-
Form 4 Hepion Pharmaceuticals, For: Sep 18 Filed by: Foster Robert T
-
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
-
Form 4 Hepion Pharmaceuticals, For: Sep 15 Filed by: Foster Robert T
Back to HEPA Stock Lookup
